Mauna Kea Technologies SA announced that it has received 2.3 million in a round of funding on May 31, 2023. The transaction included participation from new investor Tasly Pharmaceutical Group Co., Ltd.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.384 EUR | +0.92% | -0.78% | -18.47% |
Jun. 27 | The same old winners | |
Jun. 26 | Mauna Kea Technologies SA Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12.9 CNY | +0.23% | 0.00% | 2.66B | ||
0.384 EUR | +0.92% | -0.78% | 26.01M | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.47% | 26.01M | |
-27.91% | 16.33B | |
-56.07% | 2.17B | |
+19.09% | 1.88B | |
-12.63% | 1.45B | |
+29.99% | 1.32B | |
+8.32% | 853M | |
-30.60% | 799M | |
-36.50% | 726M | |
+29.48% | 622M |
- Stock Market
- Equities
- ALMKT Stock
- News Mauna Kea Technologies
- Mauna Kea Technologies SA announced that it has received €2.3 million in funding from Tasly Pharmaceutical Group Co., Ltd